Advertisement

Topics

Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus

14:38 EDT 3 Aug 2017 | SCRIP

The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might...

      

Related Stories

 

Original Article: Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus

NEXT ARTICLE

More From BioPortfolio on "Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus"

Quick Search
Advertisement
 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...